CSL Behring's mission is to discover, develop, and deliver our innovative therapies that improve the patients' quality of life.
In the event of a positive result, We will enter into collaboration agreements to address implement transactions that are aligned with our business employees must contact CSL Global Trade Compliance partnership aspects, including the respect and protection activity, have clear commercial objectives, and do not rely for further investigation.
Phase III Phase II/III Phase III AAT (CSL964) AAT (CSL964) Clazakizumab (CSL300) treatment study in MODULAATE IMAGINE trial Interleukin 6 Blockade Modifying Antibody- collaboration with BMT prevention study Mediated Graft Injury and Estimated CTN (NHLBI/NCI) Glomerular Filtration Rate (eGFR) Decline 1 2 3
CSL continues to provide medicines to patients around the world.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
Innovation is in our DNA and is the core of everything we do at CSL Behring.
CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
CSL / Momenta Collaboration •
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19